Stay updated on Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.

Latest updates to the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedExpanded the study's Locations section to include a comprehensive list of site locations across multiple regions. The update covers locations across the United States, Canada, Australia, and numerous other countries.SummaryDifference2%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed. This update changes only metadata/version information and does not affect study details or page functionality.SummaryDifference0.0%

- Check42 days agoChange DetectedPublications section now includes notes that publications are provided voluntarily and auto-filled from PubMed. The page revision is shown as Revision: v3.3.1.SummaryDifference0.0%

- Check50 days agoChange DetectedThe lapse in government funding notice has been removed from the page, and other content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedPublications and results related to KEYNOTE-564 were added, including a 2024 NEJM article, and the study record dates were updated.SummaryDifference0.1%

- Check93 days agoChange DetectedAdded a time-sensitive operating status notice and funding-related disclaimer, and updated the version to v3.2.0 (removing v3.1.0).SummaryDifference1%

Stay in the know with updates to Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.